TrialBlood2019
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Jo Howard et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
51 papers cite it
this papertrialcites it